FIG. 2.

A) Expression of mRNA for steroidogenic pathway enzymes in human endometrial stromal cells from eutopic endometrium from women with (n = 7) and without endometriosis (n = 5) treated with 0.5 mM 8-Br-cAMP for 96 h, expressed as fold change to the expression in 96-h no-treatment controls, as revealed by real-time RT-PCR. *Significance accepted at P ≤ 0.05 (Mann-Whitney test). Error bars represent ± SEM. B) Expression of IGFBP1 and PRL mRNA in endometrial stromal fibroblasts (hESFs) from women with (n = 7) and without endometriosis (n = 5) decidualized in vitro with 0.5 mM 8-Br-cAMP for 96 h, expressed as fold change to the expression in 96-h no-treatment controls (left side of B) and expression of IGFBP1 and PRL mRNA in hESFs from women with (n = 20) and without endometriosis (n = 7) decidualized in vitro for 14 days with P₄, expressed as fold change to the expression in 14 days no hormone controls (right side of B), as revealed by real-time RT-PCR. The y-axis is presented as a log scale. *Significance accepted at P ≤ 0.05 (Mann-Whitney test). Error bars represent ± SEM. C) Levels of secreted IGFBP1 and PRL in culture medium from cultured hESFs from women with (n = 7) and without (n = 5) endometriosis decidualized in vitro with 0.5 mM 8-Br-cAMP for 96 h. *Significance accepted at P ≤ 0.05 (two-tailed type 3 Student t-test). Error bars represent ± SEM.